OXiris for Abdominal SEptic Shock (OASES Study)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRenJi Hospital

About this trial

This study innovatively utilizes multi-modal hemodynamic monitoring (Norepinephrine equivalence, NEE+Pulse indicator Continuous Cariac output, PiCCO) to investigate the optimal timing of initiation of oXiris in abdominal infection-associated septic shock patients and to investigate prognosis on sepsis phenotypes undergoing oXiris therapy.

Eligibility criteria

Qualifiers

Age ≥18 years;

Weight ≥30 kg;

Intra-abdominal infection (blood or abdominal drainage fluid culture positive for Gram-negative bacteria or suspected to be caused by a Gram-negative agent);

Diagnostic septic shock (Sepsis 3.0): Sepsis was defined as "life-threatening organ dysfunction caused by a dysregulated host response to infection" with organ dysfunction defined as an increase in qSOFA ⩾2 points. Septic shock was defined as sepsis requiring vasoactive therapy to maintain mean arterial pressure (MAP) ⩾ 65 mmHg and lactate elevation to >2 mmol/L despite adequate volume resuscitation;

Disqualifiers

Patients with highly contagious infectious diseases, such as tuberculosis;

Pregnant and lying-in woman or lactation period;

Infection of other sites (no abdominal infection like pneumonia, central nervous system infection and so on);

CRRT cannot be performed for various reasons;

Trial design

Treatments tested in this trial

  • CRRT filter

Treatment groups

192 Participants
are divided into 2 treatment groups

Sponsors and collaborators